Issue and re-purchase of class C shares for shareholder program
STOCKHOLM — June 28, 2023 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 25 May 2023, to issue and immediately thereafter re-purchase a total of 219 843 class C shares. The shares are issued and re-purchased in accordance with the shareholder program which was adopted by the Annual General Meeting held on 25 May 2023 (“Board SHP 2023”).
DNB Bank ASA, Sweden Branch will subscribe for the entire issue of new class C shares at a subscription price of SEK 0.11 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the Board of Directors’ resolution, be re-purchased by DNB Bank ASA, Sweden Branch for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of Board SHP 2023.
The purpose of the re-purchase is to ensure delivery of shares in accordance with Board SHP 2023. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.